<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336799">
  <stage>Registered</stage>
  <submitdate>12/04/2011</submitdate>
  <approvaldate>13/04/2011</approvaldate>
  <actrnumber>ACTRN12611000384954</actrnumber>
  <trial_identification>
    <studytitle>Providac techsules for prevention of Antibiotic-Associated Diarrhea</studytitle>
    <scientifictitle>Randomized placebo-controlled, double blind, Multicentric Trial on Efficacy and Safety of Providac techsules (Lactobacillus acidophilus LA-5 and Bifidobacterium BB -12) for prevention of Antibiotic-Associated Diarrhea in Indian patients</scientifictitle>
    <utrn>nil</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Antibiotic-Associated Diarrhea</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Orally administered Providac capsules (Lactobacillus acidophilus LA5, 500 million Colony Forming Units &amp; Bifidobacterium  BB12, 500 million Colony Forming Units) twice daily  or placebo treatment, taken twice daily (alongwith antibiotic therapy commencement) after food for 14 days and followed up during this period of 14 days (at day 7 and day 14 following study medication commencement). A special name assigned to specially designed capsules-Techsules. These are Technologically innovated capsules that ensure targeted delivery of probiotics.</interventions>
    <comparator>Placebo-Glucose anhydrate and magnesium stearate</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of antibiotic associated diarrhea in a subject symptom diary</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of diarrhea in a subject symptom diary</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>adult patients who received oral systemic oral antibiotic therapy [cefadroxil or amoxicillin] for at least 5 days</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Subjects who had completed a course of systemic antibiotic in the last 7 days prior to screening.
2.	Severe infection requiring hospitalization or parenteral antibiotic therapy
3.	Pregnancy and/or lactation.
4.	Patients who were debilitated or seriously ill or immunocompromised
5.	Patients with acute infective diarrhea, septicaemia, endocarditis, uncontrolled diabetes or any malignancy
6.	Patients with symptoms or suspicion of an organic lesion of the digestive tract, or with undiagnosed abdominal pain or rectal bleeding or other GI disorder especially ulcerative colitis, Crohns disease, history of carcinomas of the bowel, malabsorption syndrome, intolerance to certain food types (lactose), functional diarrhea and functional constipation.
7.	Patients with hepatic and / or renal insufficiency.
8.	Patients with unstable hyperthyroidism or hypothyroidism.
9.	Patients who have undergone ileostomy, jejunostomy or colostomy.
10.	Patient undergoing active radiotherapy or chemotherapy.
11.	Current use of any drugs or treatments which is supposed to decrease the gastrointestinal motility or any other concomitant anti-diarrheal medication.
12.	Patients with hypersensitivity to any ingredient in the formulation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>3/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>India</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zydus Alidac,Cadila Healthcare Limited,</primarysponsorname>
    <primarysponsoraddress>Zydus Tower, Satellite Cross Roads,Ahmedabad  380015</primarysponsoraddress>
    <primarysponsorcountry>India</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Zydus Alidac,Cadila Healthcare Limited,</fundingname>
      <fundingaddress>Zydus Tower, Satellite Cross Roads,Ahmedabad 380015</fundingaddress>
      <fundingcountry>India</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Chr.Hansen</sponsorname>
      <sponsoraddress>M/s Chr. Hansen, A/S, Avedoere,1-27, Jernholmen,2650 Hvidovre, Denmark</sponsoraddress>
      <sponsorcountry>Denmark</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IEC</ethicname>
      <ethicaddress>Institute of Postgraduate Medical Education &amp; Research and SSKM Hospital, Kolkata</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>India</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Amit Bhalla</name>
      <address>Zydus Alidac,Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads,Ahmedabad  380015</address>
      <phone>+917926868543</phone>
      <fax />
      <email>amitbhalla@zyduscadila.com</email>
      <country>India</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Amit Bhalla</name>
      <address>Zydus Alidac,Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads,Ahmedabad  380015</address>
      <phone>+917926868543</phone>
      <fax />
      <email>amitbhalla@zyduscadila.com</email>
      <country>India</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Amit Bhalla</name>
      <address>Zydus Alidac,Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads,Ahmedabad  380015</address>
      <phone>+917926868543</phone>
      <fax />
      <email>amitbhalla@zyduscadila.com</email>
      <country>India</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>